Welcome to our dedicated page for Phibro Animal news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal stock.
Phibro Animal Health Corporation (PAHC) delivers essential animal health solutions and mineral nutrition products for global food production systems. This news hub provides investors and industry professionals with timely updates on corporate developments, financial performance, and operational milestones.
Access official press releases and curated analysis covering PAHC's strategic initiatives across its three core segments: Animal Health pharmaceuticals, Mineral Nutrition supplements, and Performance Products. Track updates including earnings reports, product innovations, regulatory developments, and partnership announcements that impact the livestock health sector.
This centralized resource enables stakeholders to monitor PAHC's responses to industry challenges and opportunities, from disease prevention advancements to nutritional science breakthroughs. Content is organized for efficient scanning while maintaining technical accuracy for veterinary professionals and investors alike.
Bookmark this page for direct access to PAHC's latest corporate communications and market-moving updates. Combine regular monitoring with historical context to inform your analysis of this animal health sector leader.
Phibro Animal Health Corporation (NASDAQ: PAHC) will announce its first quarter financial results on November 9, 2022, after market close. Management will host a conference call on November 10, 2022, at 9:00 AM ET. Interested parties can access the call and presentation at investors.pahc.com. A replay will be available two hours post-event. Phibro is a diversified animal health and mineral nutrition company focused on enhancing animal health for livestock and companion animals.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its Q4 and fiscal year 2022 results, highlighting a 16% rise in net sales to $255.3 million but a 56% drop in net income to $7.5 million. The full year 2022 saw net sales grow by 13% to $942.3 million, yet net income fell 10% to $49.2 million. The company expects FY 2023 net sales between $960 million and $1 billion and diluted EPS of $1.11 to $1.21. Adjusted EBITDA rose 3% year-over-year to $111.1 million. Phibro plans strategic investments despite ongoing inflationary pressures.
Phibro Animal Health Corporation (NASDAQ:PAHC) will participate in the Morgan Stanley Global Healthcare Conference on September 14, 2022, at 9:10 AM ET in New York. CFO Damian Finio and EVP Daniel Bendheim will present to financial analysts and investors. The live audio presentation can be accessed on their Investor Relations Website, with a replay available afterward. Phibro is dedicated to providing health solutions for livestock and companion animals, reinforcing its position as a global leader in animal health and nutrition.
Phibro Animal Health Corporation (NASDAQ:PAHC) will announce its fourth quarter and fiscal year 2022 financial results on August 24, 2022, post-market. A conference call will follow on August 25, 2022, at 9:00 AM ET, which can be accessed via phone or webcast. The company is a global leader in animal health and nutrition solutions, dedicated to supporting livestock and companion animal care.
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) declared a quarterly cash dividend of
Phibro Animal Health Corporation (NASDAQ:PAHC) has partnered with Rejuvenate Bio, Inc. to develop a gene therapy for Mitral Valve Disease (MVD) in dogs, a condition affecting approximately 7% of all canines, and up to 80% in breeds like Cavalier King Charles Spaniels. The aim is to create a treatment that not only halts MVD's progression but also reverses existing cardiac damage. Rejuvenate Bio plans to seek conditional approval as early as 2023, leveraging research from Harvard Medical School and the Wyss Institute to address age-related diseases.
Phibro Animal Health Corporation (NASDAQ: PAHC) released its inaugural Environmental, Social and Governance (ESG) Report, establishing baseline key performance metrics as of December 31, 2021. The Report aligns with the Sustainability Accounting Standards Board (SASB) and Global Reporting Initiative (GRI) frameworks, highlighting Phibro’s commitment to sustainable animal health. The company emphasizes its responsibility to provide safe, affordable protein sustainably as global demand rises. Phibro plans to regularly review and update its ESG metrics.
Phibro Animal Health Corporation (Nasdaq: PAHC) reported its Q3 results for the period ending March 31, 2022, showing net sales of $239.6 million, up 13% year-over-year. Net income rose to $17.7 million, a 45% increase. While diluted EPS increased by 47% to $0.44, adjusted net income fell 4% to $13.4 million, with adjusted diluted EPS decreasing by 3%. The company raised its 2022 net sales guidance to $930-$950 million, but maintained adjusted EBITDA at $110-$114 million, amid ongoing macroeconomic challenges.
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) has declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. This dividend is payable on June 22, 2022, to shareholders of record as of the close of business on June 1, 2022. Phibro specializes in developing and supplying a range of animal health and mineral nutrition products, aimed at promoting efficient livestock production.
Phibro Animal Health Corporation (NASDAQ:PAHC) will announce its third quarter financial results on May 4, 2022, after the market closes. A conference call for analysts and investors is scheduled for May 5, 2022, at 9:00 AM Eastern Time. This call will provide insights into the company's performance and future outlook. Interested participants can access the event through Phibro's investor site or by dialing the provided numbers for U.S. and international attendees.
FAQ
What is the current stock price of Phibro Animal (PAHC)?
What is the market cap of Phibro Animal (PAHC)?
